Emerging medication for the treatment of male hypogonadism (Q34276286)

1 August 2017

title

Emerging medication for the treatment of male hypogonadism. (English)

1 reference

1 August 2017

1 reference

Giovanni Corona

1 reference

1 August 2017

Mario Maggi

2 references

1 August 2017

ORCID Public Data File 2021

Giulia Rastrelli

series ordinal

object named as

Giulia Rastrelli

1 reference

1 August 2017

Linda Vignozzi

1 reference

1 August 2017

language of work or name

English

0 references

publication date

21 May 2012

1 reference

Expert Opinion on Emerging Drugs

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

239-259

1 reference

Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Update in testosterone therapy for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Development of subtype-selective oestrogen receptor-based therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Which patients with sexual dysfunction are suitable for testosterone replacement therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Endocrine aspects of male sexual dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Inventories for male and female sexual dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant human LH in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Treatment with human chorionic gonadotropin for PADAM: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Nanosizing: a formulation approach for poorly-water-soluble compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Pharmacokinetics And Relative Bioavailability Of Absorbed Testosterone After Administration Of A 1.62% Testosterone Gel To Different Application Sites In Men With Hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Dehydroepiandrosterone sulfate and longevity: new clues for an old friend

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Androgen therapy with dehydroepiandrosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

DHEA in elderly women and DHEA or testosterone in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Gonadal-hypothalamic interaction in prepubertal and pubertal man: effect of clomiphene citrate on urinary follicle-stimulating hormone and luteinizing hormone and plasma testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Letrozole versus testosterone. a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Immunolocalisation of oestrogen receptor beta in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Aromatase and regulating the estrogen:androgen ratio in the prostate gland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Distribution, metabolism and excretion of a synthetic androgen 7alpha-methyl-19-nortestosterone, a potential male-contraceptive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.683411

10.1517/14728214.2012.683411

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference